Active Cases

lass Action Financial Settlements Cases and Settlerments

Foreign Exchange (FOREX) Benchmark Rates Antitrust Litigation

Partial Settlement Amount $2.3 Billion

In re Foreign Exchange Benchmark Rates Antitrust Litigation, No. 1:13-CV-07789 (S.D.N.Y.) on behalf of all Persons or entities who, between January 1, 2003 and December 15, 2015, entered into an foreign exchange instrument directly with Defendant (as defined below), where such persons or entities were either domiciled in the United States or its territories, or if domiciled outside of the U.S. or its territories, transacted FX instruments in the U.S or its territories. FX Instrument includes FX spot transactions, forwards, FX swaps, futures, options, and any other FX instrument or FX transaction that the trading or settlement value of which is related in any way to FX rates. Additionally, eligible class members also include all persons who entered into FX Exchange-Traded Instruments, where such persons were either domiciled in the U.S. or its territories, or if domiciled outside of the U.S. or its territories, entered into FX Exchange-Traded Instruments on a U.S. exchange. FX Exchange-Traded Instruments means any and all FX Instruments that were listed for trading through an exchange, including, but not limited to, FX futures and options on FX futures. Defendants include Bank of America (Merrill Lynch, and Pierce, Fenner & Smith), Barclays, BNP Paribas, Citi, Goldman Sachs, HSBC, JPMorgan, RBS, and UBS, Credit Suisse Group AG, Credit Suisse AG, Credit Suisse Securities (USA) LLC, Deutsche Bank AG, Deutsche Bank Securities Inc., Morgan Stanley, Morgan Stanley & Co., LLC, Morgan Stanley & Co. International plc, Bank of Tokyo-Mitsubishi UFJ Ltd., RBC Capital Markets, LLC, Societe Generale S.A., and Standard Chartered plc. All of the Defendants have settled to this date, except Credit Suisse.

ISDAFIX Benchmark Rate Manipulations Antitrust Litigation

Partial Settlement Amount $408 Million

In re ISDAFix Instruments Benchmark Rates-Antitrust Litigation, No. CV-14-07126 (S.D.N.Y.) on behalf of all persons or entities, between January 1, 2006 and through January 31, 2014, who transacted in interest rate derivative or financial instruments related to interest rate derivative benchmark rates directly with a Defendant. Eligible parties include all persons or entities who entered into, received or made payments on, terminated, transacted in, or held an ISDAFix instrument in the above referenced time period. Defendants include Bank of America, N.A., Barclays Bank PLC, BNP Paribas SA, Citigroup Inc., Goldman Sachs Group, Inc., HSBC Bank USA, N.A., JPMorgan Chase & Co., The Royal Bank of Scotland (RBS), UBS AG, Wells Fargo Bank, N.A., Credit Suisse AG, New York Branch, Deutsche Bank AG, Morgan Stanley & Co., LLC, Nomura Securities International, Inc., and ICAP Capital Markets LLC.

Urethane Antitrust Litigation

Settlement $835 Million

In re Urethane [Polyether Polyol] Antitrust Litigation, No. 04-MD-1616-JWL (D. Kan.) An antitrust class action for persons and entities who purchased Polyether Polyol Products (defined below) directly from a defendant at any time from November 24, 2000 through December 31, 2003 in the United States and its territories (excluding all governmental entities, any defendants, their employees, and their respective parents, subsidiaries and affiliates). "Polyether Polyol Products" are: propylene oxide-based polyether polyols (polyols); monomeric or polymeric diphenylmethane diisocyanates (MMDI or PMDI - collectively, MDI); toluene diisocyanates (TDI); MDI-TDI blends; or propylene oxide-based polyether polyol systems (except those that also contain polyester polyols). Defendants are Bayer AG, Bayer Corporation, and Bayer MaterialScience LLC (F/K/A Bayer Polymers LLC); BASF Corporation and BASF SE (F/K/A BASF AG); The Dow Chemical Company; Huntsman International LLC; and Lyondell Chemical Company.